Day: November 12, 2021

End-to-end personalization and customer value management offering drives a 10 to 20 percent revenue lift for organizations

NEW YORK and LONDON, Nov. 12, 2021 (GLOBE NEWSWIRE) — McKinsey & Company today announced the launch of CustomerOne, a proven approach and comprehensive toolkit designed to help organizations accelerate personalization and customer value management. CustomerOne draws on advanced analytics, ready-to-use assets and tools, and agile principles to optimize each stage of the customer journey. This offering helps organizations shift from business-driven campaigns to customer-centric, data-driven campaigns that are connected, intuitive, and personalized. It is derived from a battle-tested approach that has helped marketing teams realize up to a 10 to 20 percent revenue lift.

End-to-End Personalization, Every Time
Consumers today have a heightened desire for personalization and authenticity – a desire for the right offering, content, and experience. They are fickler, prone to change, and less loyal. Recent McKinsey research shows that roughly 40 percent of consumers have changed brands or retailers over the past 18 months, and more than 80 percent of those intend to continue with these newfound shopping and purchase behaviors.

Many organizations cannot sufficiently respond to their customers’ needs due to​​ isolated and incomplete data, incomplete analytics and insights on their customers, and siloed organizational structures.

CustomerOne delivers business impact by surfacing deep consumer insights, unlocking opportunities quickly through AI-driven technology, and rapidly enhancing the range of tools a team can deploy. It pairs this with a proven agile way of working and approach to capability building – driving lasting impact. Organizations adopting this accelerated path to customer value can realize twice the impact in half the time.

“The leaders who achieve the best results from personalization and customer value management focus on long-term drivers of growth and emphasize customer lifetime value. It’s a force multiplier and a business necessity,” said Greg Kelly, senior partner and global leader for the Marketing & Sales Practice at McKinsey & Company. “Those who can activate the capability at scale can put customer lifetime value on a new trajectory – driving double-digit revenue growth, superior retention, and richer, long-term relationships.”

“The results we’re seeing – for example, driving a threefold increase of cross-product sales at a telco provider – are a testament to the power of CustomerOne. This approach delivered more than $100 million in less than 20 weeks at an iconic retailer and reduced mortgage churn at a retail bank by 20 percent.”

Personalization Propels Outperformance
By combining a robust and agile operating model with cross-functional capability building to get personalized marketing into production, marketing teams can focus on rapid activation, testing and learning, and driving impact.

Furthermore, CustomerOne gives organizations direct access to McKinsey’s exceptional specialized functions and disciplines, with more than 2,000 marketing experts and more than 180 advanced analytics practitioners.

Five ways CustomerOne helps unlock growth:

• It uses state-of-the-art machine learning and advanced analytics, powered by QuantumBlack, to quickly identify and size specific areas where personalization and customer value management can drive disproportionate value.
• It uses thousands of algorithms and actionable insights to accelerate value capture – all in a matter of weeks.
• It works with any martech stack to drive dynamic segmentation, real-time decisions, and cross-channel “last-mile” delivery.
• It uses an agile operating toolkit that has been tested by more than 300 marketing squads, allowing teams to mobilize from day one using out-of-the-box assets, boot-camp-style training, and proprietary workflow-management tool.
• It includes cross-functional capability building which empowers teams to run on their own and outperform market disruptors.

About McKinsey & Company
McKinsey & Company is a global management consulting firm committed to helping organizations realize sustainable, inclusive growth. We work with clients across the private, public, and social sectors to solve complex problems and create positive change for all their stakeholders. We combine bold strategies and transformative technologies to help organizations innovate more sustainably, achieve lasting gains in performance, and build workforces that will thrive for in this generation and the next.

About Marketing & Sales, McKinsey & Company
The mission of the McKinsey Marketing & Sales Practice is to help leaders of both consumer and business-to-business clients create Growth that Matters through meaningful transformations and marketing-driven profit. The practice helps its clients set their strategic direction, develop their marketing and sales capabilities, and connect their organization to realize the full potential of today’s omnichannel opportunities. Clients benefit from McKinsey’s experience in core areas of marketing such as branding, customer insights, marketing ROI, digital marketing, CLM pricing, and sales and channel management.

For further information please contact:
Media Contacts
US : DiGennaro Communications: MaryLiz Ghanem McKinsey-DiGennaro@digennaro-usa.com / 917-518-8422
UK : 3THINKRS : Ruth Jones / Becca Ross mckinsey@3thinkrs.com / 0208 0872843

TORONTO, Nov. 12, 2021 (GLOBE NEWSWIRE) — Digihost Technology Inc. (“Digihost” or the “Company”) (TSXV: DGHI; OTCQB: HSSHD), an innovative North American-based Bitcoin self-mining company, today announced that the Company has been approved to list on the Nasdaq Capital Market (“Nasdaq”), and that trading on Nasdaq is expected to begin on Monday, November 15, 2021, under the symbol “DGHI.” The ticker used for Digihost’s shares traded over-the-counter (OTC) under the current symbol “HSSHD” will seamlessly transition to the new ticker symbol “DGHI” on the first day of trading on Nasdaq. Digihost will also retain its listing on the TSX Venture Exchange under the symbol “DGHI.”

The Company expects the Nasdaq listing to enhance its investor profile and increase liquidity for its shareholders.

“A key goal of Digihost has been to provide our investors with greater liquidity through the listing of our shares on a major United States stock exchange. We believe that uplisting the Company’s shares from the OTC market to Nasdaq will also provide the Company with increased access to capital and institutional recognition. We are excited about this significant milestone for the Company and our shareholders and look forward to continuing to implement our growth strategy and building value for our shareholders,” commented Michel Amar, the Company’s CEO.

H.C. Wainwright & Co. served as advisor to Digihost in connection with the Nasdaq listing, and Katten Muchin Rosenman LLP represented the Company as U.S. legal counsel in connection with the Nasdaq listing. Peterson McVicar LLP serves as Canadian counsel to the Company.

About Digihost Technology Inc.

Digihost Technology Inc. is a growth-oriented blockchain technology company primarily focused on Bitcoin mining. Through its self-mining operations and joint venture agreements, the Company is currently hashing at a rate of 400PH with plans to expand to a hashrate of 3.6 EH by the end of 2022.

For further information, please contact:

Digihost Technology Inc.
www.digihost.ca
Michel Amar, Chief Executive Officer
T: 1-818-280-9758
Email: michel@digihostblockchain.com

Cautionary Statement
Trading in the securities of the Company should be considered highly speculative. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements
Except for the statements of historical fact, this news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) that are based on expectations, estimates and projections as at the date of this news release. Forward-looking information in this news release includes expectations in respect to listing and trading on Nasdaq and future plans and objectives of the Company. Other forward-looking information includes, but is not limited to, information concerning: hashrate expansion, diversification of operations, potential further improvements to profitability and efficiency across mining operations, potential for the Company’s long-term growth, and the business goals of the Company factors that could cause actual results, performance or achievements to differ materially from those described in such forward-looking information include, but are not limited to: trading volume, volatility and other factors affecting liquidity and prices for the common shares on Nasdaq; continued effects of the COVID-19 pandemic may have a material adverse effect on the Company’s performance as supply chains are disrupted and prevent the Company from operating its assets; a decrease in cryptocurrency pricing, volume of transaction activity or generally, the profitability of cryptocurrency mining; further improvements to profitability and efficiency may not be realized; the digital currency market; the Company’s ability to successfully mine digital currency on the cloud; the Company may not be able to profitably liquidate its current digital currency inventory, or at all; a decline in digital currency prices may have a significant negative impact on the Company’s operations; the volatility of digital currency prices; and other related risks as more fully set out in the Annual Information Form of the Company and other documents disclosed under the Company’s filings at www.sedar.com. The forward-looking information in this news release reflects the current expectations, assumptions and/or beliefs of the Company based on information currently available to the Company. Although the Company believes that the assumptions inherent in the forward-looking information are reasonable, forward-looking information is not a guarantee of future performance and accordingly undue reliance should not be put on such information due to the inherent uncertainty therein.

Philogen Provides Corporate Update

• Nidlegy™ and Fibromun are on track with planned timelines in pivotal clinical trials
• Fibromun shows potent activity in last-line glioblastoma in combination with Lomustine
• The OncoFAP platform shows promising results beyond radio-conjugates
• Cash & cash equivalents of €107.8M
• Philogen’s management team will hold a Webinar to discuss the news on November 12^th, 2021, at 11:00 EST / 16:00 BST / 17:00 CEST (Please find the link to this Webinar here)

Siena (Italy), 12 November 2021 – Philogen S.p.A., a clinical-stage biotechnology company focused on antibody- and small molecule-based targeted therapeutics provides an update regarding the Company’s Third Quarter Results and recent corporate developments.

Dario Neri, CEO of Philogen, commented on the results for the quarter and the evolution of the business:

“The past few months have been very important for Philogen, and I am delighted to provide an update on our pipeline and our financial position.

Our late-stage candidates Nidlegy™ and Fibromun are progressing well and patient enrolment for their pivotal clinical trials is on track. We are expecting to complete patient enrollment in the melanoma European Phase III clinical trial of Nidlegy™ in mid-2022. The recruitment of patients in Fibromun’s two European clinical studies in newly diagnosed and last-line soft tissue sarcoma is expected to be achieved by the end of 2023.

I am particularly excited about the emerging results in the Phase I/II study of Fibromun as a last–line treatment for glioblastoma, the most common and malignant primary brain tumor. Nine months after the beginning of treatment, the target lesion of the first evaluable patient has disappeared, and we look forward to seeing how long this potent response will last.

I am also pleased to see that we are making progress in the field of small molecule targeted therapeutics beyond OncoFAP-radio conjugates. OncoFAP is a ligand for the delivery of radionuclides and cytotoxic drugs. The excellent targeting performance of OncoFAP in patients with solid tumors was recently validated by PET imaging procedures, and we have now generated new exciting preclinical efficacy data with Small Molecule-Drug Conjugates based on OncoFAP.

Philogen remains committed to developing pharmaceutical products with game changing potential for difficult–to–treat conditions and is well capitalized to pursue this important goal.“

MAIN EVENTS AND RECENT HIGHLIGHTS

Proprietary products

• Nidlegy™ is a pharmaceutical product, proprietary to Philogen, consisting of two active ingredients, L19-IL2 and L19-TNF. The L19 antibody is specific to the B domain of Fibronectin, a protein expressed in tumors (and other diseases) but absent in most healthy tissues. Interleukin 2 (IL2) and Tumor Necrosis Factor (TNF) are inflammatory cytokines with anti-tumor activities.
  • Phase III European study in Stage IIIB/C melanoma – the study enrolled 187 patients as of November 12, 2021, with multiple clinical centers opened in Germany, France, Italy, and Poland
• Fibromun is a pharmaceutical product, proprietary to Philogen, consisting of the L19 antibody fused to TNF
  • European pivotal studies in soft tissue sarcoma – the studies feature the participation of multiple clinical centers in Germany, Spain, Italy, and Poland

• Phase I/II study in glioblastoma at first relapse/recurrence – the Phase I part of the study foresees three cohorts (3-6 subjects per cohort), in which patients receive escalating doses of Fibromun and Lomustine. All patients in the first cohort have been enrolled. The historical response rate for recurrent glioblastoma patients treated with Lomustine monotherapy is 4.3%. However, in recurrent glioblastoma patients with unmethylated MGMT promoter status the responses are close to 0% (Wick et al., J Clin Oncol 2010, 28,1168; Weller and Le Rhun et al., Cancer Treat Rev 2020, 87,102029). In the first treated patient (with unmethylated MGMT promoter), the target glioblastoma lesion has disappeared at nine months after treatment start. Philogen is now planning to further explore different administration schedules in a new clinical trial, which is expected to start in 2022 and which will allow for the collection of more information on the combination treatment.

• OncoFAP is a small organic molecule, proprietary to Philogen group, with ultra-high affinity for Fibroblast Activation Protein (FAP). The product has the ability to selectively localize in a variety of solid tumors and metastatic lesions.
  • OncoFAP-radio conjugates – excellent targeting properties of OncoFAP in patients with various tumor types. Clinicians at the Department of Nuclear Medicine of the University Hospital Münster have used OncoFAP radiolabeled with gallium-68 (OncoFAP-68Ga) to detect neoplastic lesions of both primary and metastatic origin. Of note is the intense uptake in the tumor and the low absorption in healthy organs (including kidneys) only one hour after intravenous administration of the drug. Thus, imaging results in cancer patients confirmed the excellent properties of OncoFAP observed in preclinical models, which have been published by the Philogen group in the Proceedings of the National Academy of Sciences U.S.A. Clinical investigations of the therapeutic agent (OncoFAP-177Lu) are expected to start in 2022.
  • OncoFAP-drug conjugates – these drugs consist of (i) the OncoFAP ligand, (ii) a cleavable linker and (iii) a cytotoxic payload, which is released selectively at the tumor site. Scientists at Philogen’s R&D center have recently discovered the optimal cleavable linker leading to complete tumor eradications in preclinical models of cancer, when administered as single agent. Philogen has discovered yet another potential clinical candidate that will expand the clinical stage pipeline over the next few years.

Partnered products

• Dekavil is a pharmaceutical product, licensed to Pfizer, consisting of the F8 antibody specific to the A domain of Fibronectin (EDA) fused to interleukin-10 (IL10). EDA is a protein abundantly expressed at sites of inflammation, but it is virtually undetectable in healthy tissues. IL10 is an inflammatory cytokine suitable for the treatment of chronic inflammatory diseases
  • The product will be investigated in novel clinical studies as a potential treatment in patients with certain chronic inflammatory conditions

FINANCIAL UPDATE

• Philogen ended the third quarter of 2021 with cash and cash equivalents of €107.829M compared to €61.943M on December 31, 2020.
• The net financial position on September 30, 2021, was €90.905M compared to a positive net financial position of €44.238M on December 31, 2020 (an overall increase of over 100%).
• The change in the net financial position compared to December 31, 2020, was mainly due to the proceeds raised during the Initial Public Offering on March 3, 2021, amounting to €65.404M net of commissions paid to the syndicate for the institutional placement and costs related to the issue of new shares of approximately €3.635M.

Philogen Group Description

Philogen is an Italian-Swiss company active in the biotechnology sector, specialized in the research and development of pharmaceutical products for the treatment of highly lethal diseases. The Group mainly discovers and develops targeted anticancer drugs, exploiting high-affinity ligands for tumor markers (also called tumor antigens). These ligands – human monoclonal antibodies or small organic molecules – are identified using Antibody Phage Display Libraries and DNA-Encoded Chemical Library technologies.

The Group’s main therapeutic strategy for the treatment of these diseases is represented by the so-called tumor targeting. This approach is based on the use of ligands capable of selectively delivering very potent therapeutic active ingredients (such as pro-inflammatory cytokines) to the tumor mass, sparing healthy tissues. Over the years, Philogen has mainly developed monoclonal antibody-based ligands that are specific for antigens expressed in tumor-associated blood vessels, but not expressed in blood vessels associated with healthy tissues. These antigens are usually more abundant and more stable than those expressed directly on the surface of tumor cells. This approach, so called vascular targeting, is used for most of the projects pursued by the Group.

The Group’s objective is to generate, develop and market innovative products for the treatment of diseases for which medical science has not yet identified satisfactory therapies. This is achieved by exploiting (i) proprietary technologies for the isolation of ligands that react with antigens present in certain diseases, (ii) experience in the development of products targeted at the tissues affected by the disease, (iii) experience in drug manufacturing and development, and (iv) an extensive portfolio of patents and intellectual property rights.

Although the Group’s drugs are primarily oncology applications, the targeting approach is also potentially applicable to other diseases, such as certain chronic inflammatory diseases.

FOR MORE INFORMATION:

Philogen – Investor Relations

IR@philogen.com – Emanuele Puca | Investor Relations

Consilium Strategic Communications contacts

Mary-Jane Elliott, Davide Salvi

Philogen@consilium-comms.com